ZYBT Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.99
- P/S (TTM)
- 0.30
- EV/EBITDA
- 21.76
Profitability & growth
- ROE (TTM)
- -25.2%
- Operating margin
- -77.0%
- Revenue growth YoY
- -40.9%
- Dividend yield
- —
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Zhengye Biotechnology Holding Limited Ordinary Shares
Company profileZhengye Biotechnology Holding Limited (Ticker: ZYBT) is a forward-thinking biotechnology company dedicated to the development and commercialization of cutting-edge biopharmaceutical products. Leveraging proprietary technologies and a promising product pipeline, ZYBT is strategically positioned to meet critical medical needs and improve treatment outcomes across various therapeutic areas. With a strong focus on research and development, the company is committed to driving growth and delivering value to its investors, while upholding high standards of quality and innovation in an increasingly…
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- NO.1 LIANMENG ROAD, JILIN, CHINA
- Fiscal year end
- December
- Latest quarter
- Dec 31, 2025
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer